Captrust Financial Advisors Increases Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Captrust Financial Advisors grew its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 22.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 5,825 shares of the company's stock after buying an additional 1,078 shares during the quarter. Captrust Financial Advisors' holdings in IDEXX Laboratories were worth $2,408,000 at the end of the most recent reporting period.

Several other hedge funds have also made changes to their positions in the company. Balyasny Asset Management L.P. raised its stake in IDEXX Laboratories by 230.4% in the fourth quarter. Balyasny Asset Management L.P. now owns 2,455 shares of the company's stock valued at $1,015,000 after buying an additional 1,712 shares during the last quarter. Bamco Inc. NY raised its stake in IDEXX Laboratories by 4.3% in the fourth quarter. Bamco Inc. NY now owns 2,005,522 shares of the company's stock valued at $829,163,000 after buying an additional 82,264 shares during the last quarter. Banque Transatlantique SA purchased a new stake in IDEXX Laboratories in the fourth quarter valued at about $2,681,000. Benjamin Edwards Inc. raised its stake in IDEXX Laboratories by 77.5% in the fourth quarter. Benjamin Edwards Inc. now owns 3,337 shares of the company's stock valued at $1,380,000 after buying an additional 1,457 shares during the last quarter. Finally, BLI Banque de Luxembourg Investments purchased a new stake in IDEXX Laboratories in the fourth quarter valued at about $48,882,000. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have commented on IDXX. Stifel Nicolaus decreased their price target on IDEXX Laboratories from $450.00 to $420.00 and set a "hold" rating for the company in a research note on Monday, April 14th. StockNews.com raised IDEXX Laboratories from a "hold" rating to a "buy" rating in a report on Friday, May 9th. Bank of America increased their price objective on IDEXX Laboratories from $475.00 to $535.00 and gave the company a "neutral" rating in a report on Tuesday, February 4th. Piper Sandler increased their price objective on IDEXX Laboratories from $435.00 to $510.00 and gave the company a "neutral" rating in a report on Monday, February 10th. Finally, Morgan Stanley increased their price objective on IDEXX Laboratories from $548.00 to $558.00 and gave the company an "overweight" rating in a report on Monday, May 5th. Three analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $524.75.

IDEXX Laboratories Stock Performance

IDEXX Laboratories stock traded up $6.11 during midday trading on Friday, hitting $518.10. 524,927 shares of the company were exchanged, compared to its average volume of 649,734. The firm has a market capitalization of $41.67 billion, a PE ratio of 48.56, a price-to-earnings-growth ratio of 3.41 and a beta of 1.52. IDEXX Laboratories, Inc. has a fifty-two week low of $356.14 and a fifty-two week high of $545.43. The business has a fifty day simple moving average of $431.28 and a two-hundred day simple moving average of $431.28. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.95 and a current ratio of 1.31.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The company reported $2.96 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.93 by $0.03. The company had revenue of $998.43 million for the quarter, compared to the consensus estimate of $998.25 million. IDEXX Laboratories had a return on equity of 55.82% and a net margin of 22.78%. IDEXX Laboratories's revenue for the quarter was up 3.6% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.71 earnings per share. On average, sell-side analysts forecast that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.